My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Gilead Sciences (NQ:GILD)

151.40 +0.28 (+0.19%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

51 52 Next >

Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today ↗

June 06, 2023

Via Benzinga

ImmunoGen, Day One Surge On Cancer Drug Updates, But Arcus Crashes ↗

June 05, 2023

ImmunoGen and Day One gained Monday on their updates at a cancer treatment conference.

Via Investor's Business Daily

3 Dividend Stocks You Can Buy Without Any Hesitation ↗

June 03, 2023

The choices are easy with these stocks.

Via The Motley Fool

The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree ↗

June 02, 2023

Big Pharma is facing a patent cliff that could siphon off billions in revenue.

Via Investor's Business Daily

3 Undervalued Biotech Stocks to Buy Before They Blast Off ↗

June 02, 2023

Fundamental analysis makes these three undervalued biotech stocks to buy plus they have other catalysts that make them compelling.

Via InvestorPlace

A Look Into Gilead Sciences' Debt ↗

May 16, 2023

Via Benzinga

Looking Into Gilead Sciences's Recent Short Interest ↗

May 12, 2023

Via Benzinga

Gilead Sciences Stock: Bear vs. Bull ↗

May 12, 2023

The S&P 500 has outperformed Gilead over the past five years.

Via The Motley Fool

Stocks Going Ex-Dividend In June 2023 ↗

May 27, 2023

The following is a short list of some of the many stocks going ex-dividend during the next month, which can be helpful for traders and investors interested in the stock trading technique known as...

Via Talk Markets

10 Health Care Stocks Whale Activity In Today's Session ↗

May 26, 2023

Via Benzinga

Arcus Biosciences Soars On Roche's 'Meaningful' Results In A New Cancer Drug Class ↗

May 26, 2023

Roche tested its treatment in patients with liver cancer and found "meaningful" results.

Via Investor's Business Daily

Gilead Sciences Stock Reaches 80-Plus Relative Strength Rating Benchmark ↗

May 25, 2023

On Thursday, Gilead Sciences stock had its Relative Strength (RS) Rating upgraded to 81, up from 78 a day earlier.

Via Investor's Business Daily

3 Relatively Safe Stocks to Buy if a Recession Is on the Way ↗

May 20, 2023

If the economy falters, these stocks should hold up better than most.

Via The Motley Fool

$100 Invested In This Stock 20 Years Ago Would Be Worth $1,300 Today ↗

May 04, 2023

Via Benzinga

Expert Ratings for Gilead Sciences ↗

May 01, 2023

Via Benzinga

Gilead Sciences (GILD) Q1 2023 Earnings Call Transcript ↗

April 28, 2023

GILD earnings call for the period ending March 31, 2023.

Via The Motley Fool

Gilead Posts Bullish Cancer Drug Sales, But Profit Questions Linger ↗

April 27, 2023

The company sells Trodelvy and two cell therapies. Sales of all three surged.

Via Investor's Business Daily

3 Analyst Upgrades That Smart Investors Won’t Ignore ↗

May 17, 2023

In many cases, analyst upgrades can point investors to opportunities like the ones in the stocks on this list.

Via InvestorPlace

GDC Stock Alert: Why Is GD Culture Group Up 106% Today? ↗

May 16, 2023

GD Culture (GDC) stock is rocketing higher on Tuesday with investors reacting to the company's earnings report for Q1 2023.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For May 16, 2023 ↗

May 16, 2023

Via Benzinga

Why Is Guardforce AI (GFAI) Stock Up Today? ↗

May 16, 2023

Guardforce AI (GFAI) stock is on the rise Tuesday after the AI company announced the closing of a public share offering.

Via InvestorPlace

GILD Stock Price Predictions: Is Gilead Sciences Really Worth $100? ↗

May 16, 2023

Gilead Sciences (GILD) stock is a hot topic on Tuesday as a new price target predicts a roughly 28% upside for the shares.

Via InvestorPlace

Gilead Sciences To Rally Around 28%? Here Are 10 Other Analyst Forecasts For Tuesday ↗

May 16, 2023

Morgan Stanley raised the price target for DraftKings Inc. (NASDAQ: DKNG) from $23 to $25. Morgan Stanley analyst Stephen Grambling maintained an Overweight rating. DraftKings shares fell 0.2% to close...

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 09, 2023

Via Benzinga

American Express, Gilead Sciences And This US Oil Giant On CNBC's 'Final Trades' ↗

May 08, 2023

On CNBC’s "Halftime Report Final Trades," Rob Sechan of New Edge Capital Group said Gilead Sciences, Inc. (NASDAQ: GILD) is a very defensive, steady growth play.

Via Benzinga

2 Magnificent Dividend Stocks to Buy Before the Next Recession ↗

May 05, 2023

The healthcare sector is a good place to find recession-proof stocks.

Via The Motley Fool

Gilead Sciences Stock Has Only Done This in 1 of the Past 7 Years ↗

May 04, 2023

Should you buy Gilead Sciences stock despite its poor track record?

Via The Motley Fool

Johnson & Johnson Ignites CAR-T Ambitions With Licensing Pact With Cellular Biomedicine ↗

May 02, 2023

Johnson & Johnson's (NYSE: JNJ) pharma unit Janssen

Via Benzinga

Gilead vs. CDC: The $1B Showdown Over HIV Drug Profits ↗

May 02, 2023

Gilead Sciences Inc (NASDAQ: GILD) is reportedly looking to fight claims that it owes the U.S. government a share of over $1 billion in profits from its HIV-treatment drug Truvada that could help...

Via Benzinga

Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks? ↗

April 28, 2023

Experts fear a change in how Medicare buys drugs could slam biotech and pharma companies.

Via Investor's Business Daily

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

51 52 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.